Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04621435 · ClinicalTrials.gov registry record · Phase 1
Imaging of Solid Tumors Using FAP-2286
A Phase 1 study of Metastatic Cancer and Solid Tumors, Adult, sponsored by Thomas Hope.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 191
- Enrollment target
- 1
- Study location
NCT04621435: Recruiting Phase 1 study of Metastatic Cancer and Solid Tumors, Adult, sponsored by Thomas Hope.
NCT04621435 is a Phase 1 study of Metastatic Cancer and Solid Tumors, Adult that is actively recruiting participants, run by Thomas Hope. The registered enrollment target is 191 participants, below the 442-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04621435, a Phase 1 study of Metastatic Cancer and Solid Tumors, Adult, is actively recruiting participants, sponsored by Thomas Hope.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 191 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.
Primary Outcome
The frequency and severity of treatment emergent adverse events following FAP-2286 injection will be descriptively reported as classified and graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Conditions Studied
Interventions
- DRUG Gallium-68 labelled (68Ga-) FAP-2286
- PROCEDURE Positron Emission Tomography (PET) imaging
- DRUG Copper-64 labeled (64Cu-) FAP-2286
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT04621435 shows while recruiting
NCT04621435 is an interventional study that assigns participants to a tested intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, below the 442-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (57% lower).
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Gallium-68 labelled (68Ga-) FAP-2286 is the first listed.
NCT04621435 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04621435 about?
NCT04621435 is a clinical study titled "Imaging of Solid Tumors Using FAP-2286". This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast A...
What is the current status of trial NCT04621435?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 191 participants. The study started on 2020-12-14. Estimated completion is 2026-12-31.
What conditions does trial NCT04621435 study?
This clinical trial studies the following conditions: Metastatic Cancer, Solid Tumors, Adult.
What interventions are being tested in trial NCT04621435?
The interventions under investigation include: Gallium-68 labelled (68Ga-) FAP-2286 (DRUG), Positron Emission Tomography (PET) imaging (PROCEDURE), Copper-64 labeled (64Cu-) FAP-2286 (DRUG).
Who is sponsoring clinical trial NCT04621435?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04621435 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04621435's enrollment target sits among peer trials
191 24th of 109 higher than 86 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI